Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Autor: Passaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Azuma, K., Juan-Vidal, O., Cobo, M., Felip, E., Girard, N., Cortot, A.B., Califano, R., Cappuzzo, F., Owen, S., Popat, S., Tan, J.-L., Salinas, J., Tomasini, P., Gentzler, R.D., William, W.N., Jr., Reckamp, K.L., Takahashi, T., Ganguly, S., Kowalski, D.M., Bearz, A., MacKean, M., Barala, P., Bourla, A.B., Girvin, A., Greger, J., Millington, D., Withelder, M., Xie, J., Sun, T., Shah, S., Diorio, B., Knoblauch, R.E., Bauml, J.M., Campelo, R.G., Cho, B.C.

Publikováno v: In Annals of Oncology January 2024 35(1):77-90

1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)

Autor: Sandhu, S.K., Gotto, G., Vera-Badillo, F.E., Byun, S-S., Cutuli, H.J., Gomes, A.J.P.D.S., Helissey, C., Karsh, L.I., Peer, A., Preto, D.D., Pu, Y-S., Ravilla, R., Roubaud, G., Skoneczna, I.A., Kim, W., Espina, B., Withelder, M., Urtishak, K., Francis, P.S.J., Saad, F.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S993-S993

Patient-reported outcomes in non-small cell lung cancer: psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials.

Autor: Houts CR; Vector Psychometric Group, LLC, Chapel Hill, NC, USA., Savord A; Vector Psychometric Group, LLC, Chapel Hill, NC, USA., Gardner MJ; Vector Psychometric Group, LLC, Chapel Hill, NC, USA.; Department of Psychology, Arizona State University, Tempe, AZ, USA., Mattera M; Patient-Reported Outcome Consortium, Critical Path Institute (C-Path), Tucson, AZ, USA., Peipert JD; Feinberg School of Medicine, Northwestern University, Evanston, IL, USA., Agrawal T; Janssen Global Services, LLC, Horsham, PA, USA., Baig M; Janssen Global Services, LLC, Horsham, PA, USA., Barala P; Janssen Research and Development, LLC, Spring House, PA, USA., Bauml J; Janssen Global Services, LLC, Horsham, PA, USA., Diorio B; Janssen Research and Development, Titusville, NJ, USA., Girvin A; Janssen Global Services, LLC, Horsham, PA, USA., Sermon J; Janssen Pharmaceutica NV, Beerse, Belgium., Shah S; Janssen Research and Development, LLC, Spring House, PA, USA., Withelder M; Janssen Research and Development, LLC, Malvern, PA, USA., Wortman-Vayn H; Janssen Global Services, LLC, Raritan, NJ, USA., Schuchard J; Janssen Global Services, LLC, Horsham, PA, USA. JSchucha@its.jnj.com.

Publikováno v: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2024 Dec 05. Date of Electronic Publication: 2024 Dec 05.